{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T12:11:35Z","timestamp":1761394295394},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"published-print":{"date-parts":[[2011,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Replicative phenotypic HIV resistance testing (rPRT) uses recombinant infectious virus to measure viral replication in the presence of antiretroviral drugs. Due to its high sensitivity of detection of viral minorities and its dissecting power for complex viral resistance patterns and mixed virus populations rPRT might help to improve HIV resistance diagnostics, particularly for patients with multiple drug failures. The aim was to investigate whether the addition of rPRT to genotypic resistance testing (GRT) compared to GRT alone is beneficial for obtaining a virological response in heavily pre-treated HIV-infected patients.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients with resistance tests between 2002 and 2006 were followed within the Swiss HIV Cohort Study (SHCS). We assessed patients' virological success after their antiretroviral therapy was switched following resistance testing. Multilevel logistic regression models with SHCS centre as a random effect were used to investigate the association between the type of resistance test and virological response (HIV-1 RNA &lt;50 copies\/mL or \u22651.5log reduction).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 1158 individuals with resistance tests 221 with GRT+rPRT and 937 with GRT were eligible for analysis. Overall virological response rates were 85.1% for GRT+rPRT and 81.4% for GRT. In the subgroup of patients with &gt;2 previous failures, the odds ratio (OR) for virological response of GRT+rPRT compared to GRT was 1.45 (95% CI 1.00-2.09). Multivariate analyses indicate a significant improvement with GRT+rPRT compared to GRT alone (OR 1.68, 95% CI 1.31-2.15).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In heavily pre-treated patients rPRT-based resistance information adds benefit, contributing to a higher rate of treatment success.<\/jats:p><\/jats:sec>","DOI":"10.1186\/1479-5876-9-14","type":"journal-article","created":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T11:29:50Z","timestamp":1362137390000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals - the Swiss HIV Cohort Study"],"prefix":"10.1186","volume":"9","author":[{"given":"Jan","family":"Fehr","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tracy R","family":"Glass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00e9verine","family":"Louvel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Hamy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans H","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viktor","family":"von Wyl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrg","family":"B\u00f6ni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine","family":"Yerly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philippe","family":"B\u00fcrgisser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Cavassini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph A","family":"Fux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Hirschel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro","family":"Vernazza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gladys","family":"Martinetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enos","family":"Bernasconi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huldrych F","family":"G\u00fcnthard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Battegay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heiner C","family":"Bucher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Klimkait","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the Swiss HIV Cohort Study","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,1,21]]},"reference":[{"key":"672_CR1","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0140-6736(08)61113-7","volume":"372","author":"The Antiretroviral Therapy Cohort Collaboration","year":"2008","unstructured":"The Antiretroviral Therapy Cohort Collaboration: Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. The Lancet. 2008, 372: 293-9. 10.1016\/S0140-6736(08)61113-7.","journal-title":"The Lancet"},{"key":"672_CR2","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S0140-6736(02)09411-4","volume":"360","author":"M Egger","year":"2002","unstructured":"Egger M, May M, Ch\u00eane G, Phillips AN, Ledergerber B, Dabis F, Costagliola D, D'Arminio Monforte A, de Wolf F, Reiss P, Lundgren JD, Justice AC, Staszewski S, Leport C, Hogg RS, Sabin CA, Gill MJ, Salzberger B, Sterne JA, ART Cohort Collaboration: Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. The Lancet. 2002, 360: 119-29. 10.1016\/S0140-6736(02)09411-4.","journal-title":"The Lancet"},{"key":"672_CR3","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1097\/QAD.0b013e32802ef30c","volume":"21","author":"VD Lima","year":"2007","unstructured":"Lima VD, Hogg RS, Harrigan PR, Moore D, Yip B, Wood E, Montaner JS: Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS. 2007, 21: 685-92. 10.1097\/QAD.0b013e32802ef30c.","journal-title":"AIDS"},{"key":"672_CR4","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S0140-6736(06)69152-6","volume":"368","author":"MT May","year":"2006","unstructured":"May MT, Sterne JA, Costagliola D, Sabin CA, Phillips AN, Justice AC, Dabis F, Gill J, Lundgren J, Hogg RS, de Wolf F, F\u00e4tkenheuer G, Staszewski S, d'Arminio Monforte A, Egger M: Antiretroviral Therapy (ART) Cohort Collaboration. HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis. The Lancet. 2006, 368: 451-8. 10.1016\/S0140-6736(06)69152-6.","journal-title":"The Lancet"},{"key":"672_CR5","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1056\/NEJM199803263381301","volume":"338","author":"FJ Palella Jr","year":"1998","unstructured":"Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. The New England journal of medicine. 1998, 338: 853-60. 10.1056\/NEJM199803263381301.","journal-title":"The New England journal of medicine"},{"key":"672_CR6","first-page":"1","volume-title":"Department of Health and Human Services DHHS","author":"Panel on Antiretroviral Guidelines for Adults and Adolescents","year":"2009","unstructured":"Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services DHHS. 2009, 1-161. [http:\/\/aidsinfo.nih.gov\/contentfiles\/AdultandAdolescentGL.pdf]"},{"key":"672_CR7","volume-title":"EACS-guidelines","author":"European AIDS Clinical Society Guidelines","year":"2009","unstructured":"European AIDS Clinical Society Guidelines: Guidelines for the Clinical Management and Treatment of HIV-infected Adults in Europe. EACS-guidelines. 2009, Version 5, [http:\/\/www.europeanaidsclinicalsociety.org\/guidelines.asp]"},{"issue":"304 (3)","key":"672_CR8","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1001\/jama.2010.1004","volume":"21","author":"MA Thompson","year":"2010","unstructured":"Thompson MA, Aberg JA, Cahn P, Montaner JS, Rizzardini G, Telenti A, Gatell JM, G\u00fcnthard HF, Hammer SM, Hirsch MS, Jacobsen DM, Reiss P, Richman DD, Volberding PA, Yeni P, Schooley RT, International AIDS Society-USA: Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA. 2010, 21 (304 (3)): 321-33. 10.1001\/jama.2010.1004.","journal-title":"JAMA"},{"key":"672_CR9","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1086\/589297","volume":"47","author":"MS Hirsch","year":"2008","unstructured":"Hirsch MS, G\u00fcnthard HF, Schapiro JM, Brun-V\u00e9zinet F, Clotet B, Hammer SM, Johnson VA, Kuritzkes DR, Mellors JW, Pillay D, Yeni PG, Jacobsen DM, Richman DD, International AIDS Society-USA: Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis. 2008, 47: 266-85. 10.1086\/589297.","journal-title":"Clin Infect Dis"},{"key":"672_CR10","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1089\/aid.1998.14.869","volume":"14","author":"HF G\u00fcnthard","year":"1998","unstructured":"G\u00fcnthard HF, Wong JK, Ignacio CC, Havlir DV, Richman DD: Comparative performance of high-density oligonucleotide sequencing and dideoxynucleotide sequencing of HIV type 1 pol from clinical samples. AIDS Res Hum Retroviruses. 1998, 14: 869-876. 10.1089\/aid.1998.14.869.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"672_CR11","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1089\/088922202753472801","volume":"18","author":"R Schuurman","year":"2002","unstructured":"Schuurman R, Brambilla D, de Groot T, Huang D, Land S, Bremer J, Benders I, Boucher CA: Underestimation of HIV type 1 drug resistance mutations: results from the ENVA-2 genotyping proficiency program. AIDS Res Hum Retroviruses. 2002, 18: 243-248. 10.1089\/088922202753472801.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"672_CR12","doi-asserted-by":"publisher","first-page":"4999","DOI":"10.1128\/JVI.75.11.4999-5008.2001","volume":"75","author":"L Bacheler","year":"2001","unstructured":"Bacheler L, Jeffrey S, Hanna G, D'Aquila R, Wallace L, Logue K, Cordova B, Hertogs K, Larder B, Buckery R, Baker D, Gallagher K, Scarnati H, Tritch R, Rizzo C: Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J Virol. 2001, 75: 4999-5008. 10.1128\/JVI.75.11.4999-5008.2001.","journal-title":"J Virol"},{"key":"672_CR13","doi-asserted-by":"publisher","first-page":"3850","DOI":"10.1093\/nar\/gkg575","volume":"31","author":"N Beerenwinkel","year":"2003","unstructured":"Beerenwinkel N, D\u00e4umer M, Oette M, Korn K, Hoffmann D, Kaiser R, Lengauer T, Selbig J, Walter H, Geno2pheno: Estimating phenotypic drug resistance from HIV-1 genotypes. Nucleic Acids Res. 2003, 31: 3850-5. 10.1093\/nar\/gkg575.","journal-title":"Nucleic Acids Res"},{"key":"672_CR14","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1097\/00126334-200303010-00005","volume":"32","author":"F Mazzotta","year":"2003","unstructured":"Mazzotta F, Lo Caputo S, Torti C, Tinelli C, Pierotti P, Castelli F, Lazzarin A, Angarano G, Maserati R, Gianotti N, Ladisa N, Quiros-Roldan E, Rinehart AR, Carosi G: Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48-week follow-up of the Genotipo-Fenotipo di Resistenza (GenPheRex) trial. Journal of acquired immune deficiency syndromes. 2003, 32: 268-80. 10.1097\/00126334-200303010-00005.","journal-title":"Journal of acquired immune deficiency syndromes"},{"key":"672_CR15","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1177\/135965350300800604","volume":"8","author":"MJ Perez-Elias","year":"2003","unstructured":"Perez-Elias MJ, Garcia-Arota I, Mu\u00f1oz V, Santos I, Sanz J, Abraira V, Arribas JR, Gonz\u00e1lez J, Moreno A, Dronda F, Antela A, Pumares M, Mart\u00ed-Belda P, Casado JL, Geijos P, Moreno S: Phenotype or virtual phenotype for choosing antiretroviral therapy after failure: a prospective, randomized study. Antiviral therapy. 2003, 8: 577-84.","journal-title":"Antiviral therapy"},{"key":"672_CR16","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.jcv.2006.05.001","volume":"36","author":"A Holguin","year":"2006","unstructured":"Holguin A, Sune C, Hamy F, Soriano V, Klimkait T: Natural polymorphisms in the protease gene modulate the replicative capacity of non-B HIV-1 variants in the absence of drug pressure. J Clin Virol. 2006, 36: 264-71. 10.1016\/j.jcv.2006.05.001.","journal-title":"J Clin Virol"},{"key":"672_CR17","first-page":"20","volume":"21","author":"T Klimkait","year":"2002","unstructured":"Klimkait T: A sensitive replicative system to assess HIV-1 drug resistance. American clinical laboratory. 2002, 21: 20-4.","journal-title":"American clinical laboratory"},{"key":"672_CR18","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/j.1468-1293.2007.00529.x","volume":"9","author":"S Louvel","year":"2008","unstructured":"Louvel S, Battegay M, Vernazza P, Bregenzer T, Klimkait T, Hamy F: Detection of drug-resistant HIV minorities in clinical specimens and therapy failure. HIV Med. 2008, 9: 133-41. 10.1111\/j.1468-1293.2007.00529.x.","journal-title":"HIV Med"},{"key":"672_CR19","doi-asserted-by":"publisher","first-page":"F83","DOI":"10.1097\/00002030-200006160-00001","volume":"14","author":"JD Baxter","year":"2000","unstructured":"Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Hoover ML, Winters MA, Mannheimer SB, Thompson MA, Abrams DI, Brizz BJ, Ioannidis JP, Merigan TC: A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. AIDS. 2000, 14: F83-F93. 10.1097\/00002030-200006160-00001.","journal-title":"AIDS"},{"key":"672_CR20","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1097\/00002030-200202150-00008","volume":"16","author":"A Cingolani","year":"2002","unstructured":"Cingolani A, Antinori A, Rizzo MG, Murri R, Ammassari A, Baldini F, Di Giambenedetto S, Cauda R, De Luca A: Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS. 2002, 16: 369-79. 10.1097\/00002030-200202150-00008.","journal-title":"AIDS"},{"key":"672_CR21","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1016\/S0140-6736(98)12291-2","volume":"353","author":"J Durant","year":"1999","unstructured":"Durant J, Clevenbergh P, Garraffo R, Halfon P, Icard S, Del Giudice P, Montagne N, Schapiro JM, Dellamonica P: Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. The Lancet. 1999, 353: 2195-9. 10.1016\/S0140-6736(98)12291-2.","journal-title":"The Lancet"},{"key":"672_CR22","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1177\/135965350300800512","volume":"8","author":"S Haupts","year":"2003","unstructured":"Haupts S, Ledergerber B, B\u00f6ni J, Sch\u00fcpbach J, Kronenberg A, Opravil M, Flepp M, Speck RF, Grube C, Rentsch K, Weber R, G\u00fcnthard HF, Swiss HIV Cohort Study: Impact of genotypic resistance testing on selection of salvage regimen in clinical practice. Antiviral therapy. 2003, 8: 443-54.","journal-title":"Antiviral therapy"},{"key":"672_CR23","doi-asserted-by":"publisher","first-page":"e173","DOI":"10.1371\/journal.pone.0000173","volume":"2","author":"P Sendi","year":"2007","unstructured":"Sendi P, Gunthard HF, Simcock M, Ledergerber B, Schupbach J, Battegay M: Cost-Effectiveness of Genotypic Antiretroviral Resistance Testing in HIV-Infected Patients with Treatment Failure. PLoS ONE. 2007, 2: e173-10.1371\/journal.pone.0000173.","journal-title":"PLoS ONE"},{"key":"672_CR24","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1177\/135965350601100305","volume":"11","author":"M Simcock","year":"2006","unstructured":"Simcock M, Sendi P, Ledergerber B, Keller T, Sch\u00fcpbach J, Battegay M, G\u00fcnthard HF, Swiss HIV Cohort Study: A longitudinal analysis of healthcare costs after treatment optimization following genotypic antiretroviral resistance testing: does resistance testing pay off?. Antiviral therapy. 2006, 11: 305-14.","journal-title":"Antiviral therapy"},{"key":"672_CR25","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1097\/00002030-200201250-00010","volume":"16","author":"C Tural","year":"2002","unstructured":"Tural C, Ruiz L, Holtzer C, Schapiro J, Viciana P, Gonz\u00e1lez J, Domingo P, Boucher C, Rey-Joly C, Clotet B: Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS. 2002, 16: 209-18. 10.1097\/00002030-200201250-00010.","journal-title":"AIDS"},{"key":"672_CR26","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1097\/00002030-200203080-00009","volume":"16","author":"CJ Cohen","year":"2002","unstructured":"Cohen CJ, Hunt S, Sension M, Farthing C, Conant M, Jacobson S, Nadler J, Verbiest W, Hertogs K, Ames M, Rinehart AR, Graham NM: A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS. 2002, 16: 579-88. 10.1097\/00002030-200203080-00009.","journal-title":"AIDS"},{"key":"672_CR27","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1371\/journal.pctr.0010018","volume":"1","author":"G Hales","year":"2006","unstructured":"Hales G, Birch C, Crowe S, Workman C, Hoy JF, Law MG, Kelleher AD, Lincoln D, Emery S: A Randomised Trial Comparing Genotypic and Virtual Phenotypic Interpretation of HIV Drug Resistance: The CREST Study. PLoS clinical trials. 2006, 1: 18-e. 10.1371\/journal.pctr.0010018.","journal-title":"PLoS clinical trials"},{"key":"672_CR28","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1097\/00002030-200203290-00008","volume":"16","author":"JL Meynard","year":"2002","unstructured":"Meynard JL, Vray M, Morand-Joubert L, Race E, Descamps D, Peytavin G, Matheron S, Lamotte C, Guiramand S, Costagliola D, Brun-V\u00e9zinet F, Clavel F, Girard PM, Narval Trial Group: Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS. 2002, 16: 727-36. 10.1097\/00002030-200203290-00008.","journal-title":"AIDS"},{"key":"672_CR29","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1086\/381266","volume":"38","author":"SA Wegner","year":"2004","unstructured":"Wegner SA, Wallace MR, Aronson NE, Tasker SA, Blazes DL, Tamminga C, Fraser S, Dolan MJ, Stephan KT, Michael NL, Jagodzinski LL, Vahey MT, Gilcrest JL, Tracy L, Milazzo MJ, Murphy DJ, McKenna P, Hertogs K, Rinehart A, Larder B, Birx DL: Long-term efficacy of routine access to antiretroviral-resistance testing in HIV type 1-infected patients: results of the clinical efficacy of resistance testing trial. Clin Infect Dis. 2004, 38: 723-30. 10.1086\/381266.","journal-title":"Clin Infect Dis"},{"key":"672_CR30","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1097\/01.qai.0000148533.12329.96","volume":"38","author":"DT Dunn","year":"2005","unstructured":"Dunn DT, Green H, Loveday C, Rinehart A, Pillay D, Fisher M, McCormack S, Babiker AG, Darbyshire JH: A randomized controlled trial of the value of phenotypic testing in addition to genotypic testing for HIV drug resistance: evaluation of resistance assays (ERA) trial investigators. J Acquir Immune Defic Syndr. 2005, 38: 553-9. 10.1097\/01.qai.0000148533.12329.96.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"672_CR31","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s10096-005-0044-4","volume":"24","author":"HH Hirsch","year":"2005","unstructured":"Hirsch HH, Drechsler H, Holbro A, Hamy F, Sendi P, Petrovic K, Klimkait T, Battegay M: Genotypic and phenotypic resistance testing of HIV-1 in routine clinical care. European journal of clinical microbiology & infectious diseases. 2005, 24: 733-8. 10.1007\/s10096-005-0044-4.","journal-title":"European journal of clinical microbiology & infectious diseases"},{"key":"672_CR32","unstructured":"Swiss HIV Cohort Study: Ongoing multicenter research. [http:\/\/www.shcs.ch]"},{"key":"672_CR33","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1001\/archinte.167.16.1782","volume":"167","author":"V von Wyl","year":"2007","unstructured":"von Wyl V, Yerly S, B\u00f6ni J, B\u00fcrgisser P, Klimkait T, Battegay M, Furrer H, Telenti A, Hirschel B, Vernazza PL, Bernasconi E, Rickenbach M, Perrin L, Ledergerber B, G\u00fcnthard HF: Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types. Arch Intern Med. 2007, 167: 1782-90. 10.1001\/archinte.167.16.1782.","journal-title":"Arch Intern Med"},{"key":"672_CR34","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1097\/00002030-200111230-00010","volume":"15","author":"S Yerly","year":"2001","unstructured":"Yerly S, Vora S, Rizzardi P, Chave JP, Vernazza PL, Flepp M, Telenti A, Battegay M, Veuthey AL, Bru JP, Rickenbach M, Hirschel B, Perrin L: Acute HIV infection: impact on the spread of HIV and transmission of drug resistance. AIDS. 2001, 15: 2287-92. 10.1097\/00002030-200111230-00010.","journal-title":"AIDS"},{"key":"672_CR35","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1007\/s007050050447","volume":"143","author":"T Klimkait","year":"1998","unstructured":"Klimkait T, Stauffer F, Lupo E, Sonderegger-Rubli C: Dissecting the mode of action of various HIV-inhibitor classes in a stable cellular system. Arch Virol. 1998, 143: 2109-31. 10.1007\/s007050050447.","journal-title":"Arch Virol"},{"issue":"2","key":"672_CR36","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/QAI.0b013e3181ca48bf","volume":"54","author":"TR Glass","year":"2010","unstructured":"Glass TR, Battegay M, Cavassini M, De Geest S, Furrer H, Vernazza PL, Hirschel B, Bernasconi E, Rickenbach M, G\u00fcnthard HF, Bucher HC, Swiss HIV Cohort Study: Longitudinal analysis of patterns and predictors of changes in self-reported adherence to antiretroviral therapy: Swiss HIV Cohort Study. J Acquir Immune Defic Syndr. 2010, 54 (2): 197-203.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"672_CR37","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","volume":"335","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP: Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007, 335: 806-8. 10.1136\/bmj.39335.541782.AD.","journal-title":"BMJ"},{"key":"672_CR38","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1086\/597352","volume":"48","author":"V von Wyl","year":"2009","unstructured":"von Wyl V, Yerly S, B\u00fcrgisser P, Klimkait T, Battegay M, Bernasconi E, Cavassini M, Furrer H, Hirschel B, Vernazza PL, Francioli P, Bonhoeffer S, Ledergerber B, G\u00fcnthard HF: Long-term trends of HIV type 1 drug resistance prevalence among antiretroviral treatment-experienced patients in Switzerland. Clin Infect Dis. 2009, 48: 979-87. 10.1086\/597352.","journal-title":"Clin Infect Dis"},{"key":"672_CR39","first-page":"93","volume":"10","author":"C Briones","year":"2008","unstructured":"Briones C, Domingo E: Minority report: hidden memory genomes in HIV-1 quasispecies and possible clinical implications. AIDS Rev. 2008, 10: 93-109.","journal-title":"AIDS Rev"},{"key":"672_CR40","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/1742-4690-6-15","volume":"6","author":"G Rozera","year":"2009","unstructured":"Rozera G, Abbate I, Bruselles A, Vlassi C, D'Offizi G, Narciso P, Chillemi G, Prosperi M, Ippolito G, Capobianchi MR: Massively parallel pyrosequencing highlights minority variants in the HIV-1 env quasispecies deriving from lymphomonocyte sub-populations. Retrovirology. 2009, 6: 15-10.1186\/1742-4690-6-15.","journal-title":"Retrovirology"},{"key":"672_CR41","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1128\/AAC.50.2.694-701.2006","volume":"50","author":"J Snoeck","year":"2006","unstructured":"Snoeck J, Kantor R, Shafer RW, Van Laethem K, Deforche K, Carvalho AP, Wynhoven B, Soares MA, Cane P, Clarke J, Pillay C, Sirivichayakul S, Ariyoshi K, Holguin A, Rudich H, Rodrigues R, Bouzas MB, Brun-V\u00e9zinet F, Reid C, Cahn P, Brigido LF, Grossman Z, Soriano V, Sugiura W, Phanuphak P, Morris L, Weber J, Pillay D, Tanuri A, Harrigan RP, Camacho R, Schapiro JM, Katzenstein D, Vandamme AM: Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent. Antimicrob Agents Chemother. 2006, 50: 694-701. 10.1128\/AAC.50.2.694-701.2006.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1479-5876-9-14.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,29]],"date-time":"2023-06-29T20:51:45Z","timestamp":1688071905000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/1479-5876-9-14"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,21]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["672"],"URL":"https:\/\/doi.org\/10.1186\/1479-5876-9-14","relation":{},"ISSN":["1479-5876"],"issn-type":[{"type":"electronic","value":"1479-5876"}],"subject":[],"published":{"date-parts":[[2011,1,21]]},"assertion":[{"value":"9 November 2010","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2011","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2011","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"14"}}